Expression of vascular endothelial growth factor in Juvenile Angiofibroma

Hota, Ashutosh; Sarkar, Chitra; Gupta, Siddhartha Datta; Kumar, Rakesh; Bhalla, Ashu Seith; Thakar, Alok

doi:10.1016/j.ijporl.2015.03.033

Cited by 10 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A second endoscopic surgery is the recommended option when the likelihood of complete tumor resection is high, and the risk of morbidity is low . Medical therapies are in the investigative stages and there is no current consensus for their use . Ardehali et al .…”

Section: Benign Lesionsmentioning

confidence: 99%

ICAR: endoscopic skull‐base surgery

Wang

Zanation

Gardner

et al. 2019

Int Forum Allergy Rhinol

160

279

View full text Add to dashboard Cite

Background Endoscopic skull‐base surgery (ESBS) is employed in the management of diverse skull‐base pathologies. Paralleling the increased utilization of ESBS, the literature in this field has expanded rapidly. However, the rarity of these diseases, the inherent challenges of surgical studies, and the continued learning curve in ESBS have resulted in significant variability in the quality of the literature. To consolidate and critically appraise the available literature, experts in skull‐base surgery have produced the International Consensus Statement on Endoscopic Skull‐Base Surgery (ICAR:ESBS). Methods Using previously described methodology, topics spanning the breadth of ESBS were identified and assigned a literature review, evidence‐based review or evidence‐based review with recommendations format. Subsequently, each topic was written and then reviewed by skull‐base surgeons in both neurosurgery and otolaryngology. Following this iterative review process, the ICAR:ESBS document was synthesized and reviewed by all authors for consensus. Results The ICAR:ESBS document addresses the role of ESBS in primary cerebrospinal fluid (CSF) rhinorrhea, intradural tumors, benign skull‐base and orbital pathology, sinonasal malignancies, and clival lesions. Additionally, specific challenges in ESBS including endoscopic reconstruction and complication management were evaluated. Conclusion A critical review of the literature in ESBS demonstrates at least the equivalency of ESBS with alternative approaches in pathologies such as CSF rhinorrhea and pituitary adenoma as well as improved reconstructive techniques in reducing CSF leaks. Evidence‐based recommendations are limited in other pathologies and these significant knowledge gaps call upon the skull‐base community to embrace these opportunities and collaboratively address these shortcomings.

show abstract

Section: Benign Lesionsmentioning

confidence: 99%

ICAR: endoscopic skull‐base surgery

Wang

Zanation

Gardner

et al. 2019

Int Forum Allergy Rhinol

160

279

View full text Add to dashboard Cite

show abstract

“…37 With respect to estrogen receptors, two distinct subtypes-ER-α and ER-β-are now recognized. 50 These 2 receptors regulate transcription of the same genes but have a different binding affinity for estrogen and other ligands. 38 ER-α has been shown to activate protein-1 sites in the presence of estradiol, whereas ER-β has been shown to both inhibit these sites 39 and act as a down regulator of ER-α.…”

Section: Steroid Hormones and Nuclear Receptorsmentioning

confidence: 99%

“…34 VEGF has a strong association with vascular tumors 50 and, along with its receptors, has been studied in relation to JNA. 27,34,36,[50][51][52][53][54][55] Although all studies attest to increased levels of VEGF in JNA tissue, 34,36,[50][51][52][53][54]56 there is a lack of consensus on the exact cellular location of VEGF. Some studies found VEGF in both stromal and endothelial cells, 50 some predominantly in endothelial cells, 54 and others principally in stromal cells.…”

Section: Factors and Markers Of Growth Proliferation And Tissue Remodmentioning

confidence: 99%

“…VEGF has been implicated in tumorigenesis, 34,50 and as a consequence, drugs targeting VEGF signaling have been developed. 87 Based on the research assessing the role of VEGF in JNA, 27,34,36,[50][51][52][53][54][55] antiangiogenic therapy might play a role in JNA treatment. 51,87 Anti-angiogenic therapy has been used as an adjuvant treatment of histologically verified highly vascular JNAs in challenging surgical locations 87 with limited efficacy.…”

Section: Implications Of Advances In Discerning Etiologymentioning

confidence: 99%

See 1 more Smart Citation

The Genetic and Molecular Determinants of Juvenile Nasopharyngeal Angiofibroma: A Systematic Review

Doody

Adil

Trenor

et al. 2019

Ann Otol Rhinol Laryngol

View full text Add to dashboard Cite

Objective: Juvenile nasopharyngeal angiofibroma (JNA) is a rare vascular tumor of unknown etiology. Studies investigating the molecular and genetic determinants of JNA are limited by small sample size and inconsistent approaches. The purpose of this study is to examine all eligible JNA studies in aggregate, applying qualitative analysis to highlight areas of particular relevance, including potential targets for therapeutic intervention. Methods: The PubMed, MEDLINE, Embase, Web of Science, Cochrane, and CINAHL databases were screened with inclusion and exclusion criteria applied to all citations. Manuscripts investigating the genetic determinants, histopathogenesis, and heritability of juvenile nasopharyngeal angiofibroma were included. Non-English studies, case reports, and articles focusing on clinical management without original data were excluded. Full text articles were obtained. A qualitative synthesis of data was performed. Results: A total of 59 articles met criteria for inclusion. These were divided into 6 categories based on the primary topic or target discussed, (1) steroid hormone receptors, (2) chromosomal abnormalities, (3) growth factors, (4) genetic targets, (5) molecular targets, (6) Wnt cell signaling, and (7) studies that overlapped multiple of the aforementioned categories. Although relatively low n values prevent definitive conclusions to be drawn, a predominance of certain molecular targets such as vascular endothelial growth factor (VEGF) and Wnt/β-catenin pathway intermediaries is apparent. Conclusions: Although the etiology of JNA remains elusive, contemporary molecular genetic investigation holds promise for risk stratification and could form the basis of a modernized staging system. A multicenter clinical registry and linked tissue bank would further promote the search for JNA specific biomarkers.

show abstract

“…Interestingly, VEGF expression is not significantly related to the puberty status, stage of the tumor, intraoperative blood loss, and the recurrence of the JNA. 16 The VEGF has a central role in the pathways and stages of tumor angiogenesis, and especially the degradation of extracellular matrix and proliferation of vascular endothelial cells. Increased endothelial cell proliferation will further increase microvascular density as well as increase VEGF expression.…”

Section: Introductionmentioning

confidence: 99%

Vascular Endothelial Growth Factor Expression in Correlation with Stage Juvenile Nasopharyngeal Angiofibroma

Nazar

Dewi

Permana

2021

AMJ

View full text Add to dashboard Cite

Background: Juvenile Nasopharyngeal Angiofibroma (JNA) is a benign tumor of mesenchymal tissue, originating from the stromal and blood vessels with dense collagen. However, JNA has a malignant tumor-like property because it can cause erosion of surrounding bone. Vascular Endothelial Growth Factor (VEGF) plays a role in the angiogenesis process. The expression of VEGF is the best marker to determine the occurrence of angiogenesis in JNA. This study aimed to determine the correlation between VEGF expression and JNA clinical stage. Methods: This was a cross-sectional correlational analytic observational study on medical records and paraffin blocks of all patients with JNA at Dr. Hasan Sadikin General Hospital Bandung during the period of 2016 to 2019. Immunohistochemistry examination of VEGF expressions was performed and VEGF expression was rated based on staining intensity, percentage distribution, and histoscore. Data were then analyzed using the Spearman correlation test.Results: Of 24 patients, 23 males and 1 female, 58% demonstrated a strong intensity of staining. The positivity of VEGF cell percentage was identified as 26–50% (n=6 patients), 51–75% (n=11), and >75% (n=7). The median VEGF histoscores were 2.5, 6.5, and 12 in JNA stage I, stage II, and stage 3, respectively, with the greater VEGF histoscore had a higher clinical stage with a correlation coefficient of (rs) 0.723 (p=0.002). Conclusions: There is a strong correlation between increased VEGF expression and JNA clinical stage. VEGF expression can be used as a prognostic factor of JNA.

show abstract

Expression of vascular endothelial growth factor in Juvenile Angiofibroma

Cited by 10 publications

References 15 publications

ICAR: endoscopic skull‐base surgery

ICAR: endoscopic skull‐base surgery

The Genetic and Molecular Determinants of Juvenile Nasopharyngeal Angiofibroma: A Systematic Review

Vascular Endothelial Growth Factor Expression in Correlation with Stage Juvenile Nasopharyngeal Angiofibroma

Contact Info

Product

Resources

About